• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    SC 13G 1 ss4037903_sc13g.htm SCHEDULE 13G

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     



     

    Pacific Biosciences of California, Inc.
    (Name of Issuer)

     

     

    Common Stock
    (Title of Class of Securities)

     

    69404D108

     
    (CUSIP Number)

     

    September 30, 2024

     
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      



      

      

     

     
             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    France

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    18,805,980

    7

    SOLE DISPOSITIVE POWER

     

    1,501,900

    8

    SHARED DISPOSITIVE POWER

     18,805,980

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    20,307,880

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    7.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

     

     

     

     

      

     

     

     

             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG)

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    14,995,980

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     14,995,980

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,995,980

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

      

     

     

             
    1

    NAME OF REPORTING PERSONS

     EDMOND DE ROTHSCHILD FUND

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    14,862,300

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     14,862,300

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    14,862,300

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.5%

    12

    TYPE OF REPORTING PERSON

     FI

     

     

     

     

     

     

      

     

     

     

    Item 1.   (a) Name of Issuer:
        Pacific Biosciences of California, Inc.

     

        (b) Address of Issuer’s Principal Executive Offices:

    1305 O’Brien Drive

    Menlo Park, California 94025

    Item 2.   (a) Name of Person Filing:

    This Schedule 13G is being filed on behalf of each of the following persons (each, a “Reporting Person”) :

    1.EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE) (“EDRAM France”)
    2.EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG) (“EDRAM Luxembourg”)

     3.EDMOND DE ROTHSCHILD FUND (“EdR Fund”)

     

        (b) Address of Principal Business Office:

    The address of EDRAM France is 47, RUE DU FAUBOURG SAINT HONORE PARIS, FRANCE 75008.

    The address of EDRAM Luxembourg is 4, RUE ROBERT STUMPER, LUXEMBOURG L-2557.

    The address of EdR Fund is 4, RUE ROBERT STUMPER, LUXEMBOURG L-2557.

        (c) Citizenship:

    EDRAM France is a French entity

    EDRAM Luxembourg is a Luxembourg entity

    EdR Fund is a société d’investissement à capital variable (SICAV) Luxembourg formed under the laws of Luxembourg.

        (d) Title of Class of Securities:

    Common Stock

        (e) CUSIP No.:

             69404D108

     

    Item 3.      

    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J)

     

    Item 4. Ownership:

    Ownership as of September 30, 2024 is incorporated by reference to items (5) – (9) and (11) of the cover page of each Reporting Person. Both EDRAM France and EDRAM Luxembourg, management companies, may be deemed to have beneficial ownership of the securities which are the subject of this filing through the investment and/or voting discretion it exercises over its portfolios managed. Besides, EdR Fund, a société d’investissement à capital variable (SICAV) formed under the laws of Luxembourg, is the beneficial owner of more than 5% of the outstanding securities identified on this Schedule 13G.

    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not Applicable

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable

     

      

     

    Item 8. Identification and Classification of Members of the Group.

     Not Applicable

     

     

    Item 9. Notice of Dissolution of Group.

     Not Applicable

     

     

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory schemes applicable to the Reporting Persons are substantially comparable to the regulatory schemes applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

      

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  November 14, 2024

     

     

    EDMOND DE ROTHSCHILD ASSET MANAGEMENT (FRANCE)

     

    By: /s/ Benjamin Melman

    Name: Benjamin Melman

    Title: Global Chief Investment Officer

       
       
     

    EDMOND DE ROTHSCHILD ASSET MANAGEMENT (LUXEMBOURG)

     

    By: /s/ Enrique Bouillot

    Name: Enrique Bouillot

    Title: COMEX Member

     

    By: /s/ Emmanuel Vergeynst

    Name: Emmanuel Vergeynst

    Title: COMEX Member

       
       
     

    EDMOND DE ROTHSCHILD FUND

     

    By: /s/ Flavien Duval

    Name: Flavien Duval

    Title: Member of the Board

     

    By: /s/ Hervé Touchais

    Name: Hervé Touchais

    Title: Member of the Board

     

     

     

     

    Get the next $PACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings